» Articles » PMID: 33959643

Long-Term Outcomes of Successful Recanalization Compared With Optimal Medical Therapy for Coronary Chronic Total Occlusions in Patients With and Without Left Ventricular Systolic Dysfunction

Overview
Date 2021 May 7
PMID 33959643
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The number of coronary chronic total occlusion (CTO) patients with left ventricular (LV) systolic dysfunction is significant, but the clinical outcomes of these patients are rarely reported. The present retrospective cohort study aimed to investigate the long-term outcomes of successful recanalization vs. optimal medical therapy (MT) for CTOs in patients with preserved and impaired LV systolic function. A total of 1,895 patients with CTOs were stratified according to LV function. Of these, 1,420 patients (74.9%) with LV ejection fraction (LVEF) >45% and 475 patients (25.1%) with LVEF ≤45% were treated with optimal MT or successful CTO percutaneous coronary intervention (PCI). A 1:1 propensity score matching (PSM) was conducted to reduce the impact of potential confounding on the outcomes. The primary outcome was the frequency of major adverse cardiac events (MACEs). Throughout a 2.6-year follow-up and after adjusting for confounders, among patients with preserved LV function, successful CTO PCI was associated with reduced incidence of MACE (14.2 vs. 23.9%, adjusted HR 0.63, 95% CI 0.48-0.83, = 0.001) compared to MT. There was no significant difference in MACE occurrence (29.6 vs. 28.9%, adjusted HR 1.05, 95% CI: 0.71-1.56, = 0.792) between successful recanalization and MT in patients with LV systolic dysfunction. The primary outcome among patients with impaired and preserved LV systolic function after PSM was similar to that from earlier findings before PSM was conducted. A significant interaction between LV function and therapeutic strategy for MACE was observed (interaction = 0.038). Compared to MT alone for management of patients with CTOs, successful CTO PCI may reduce the risk of MACE in patients with preserved LV systolic function, but not in patients with LV dysfunction.

Citing Articles

Impact of complete revascularization on long-term clinical outcomes in patients with multi-vessel disease, including chronic total occlusion.

Yang D, Park S, Rha S, Choi S, Choi C, Choi B Heart Vessels. 2024; .

PMID: 39609270 DOI: 10.1007/s00380-024-02484-5.


The Predictive Value of the Systemic Immune-Inflammation Index for Cardiovascular Events in Chronic Total Occlusion Patients Who Prior Coronary Artery Bypass Grafting.

Zhao Y, Zhao S, Shi Y, Ma Q, Zheng Z, Wang P J Inflamm Res. 2024; 17:8611-8623.

PMID: 39539724 PMC: 11559419. DOI: 10.2147/JIR.S486692.


Percutaneous Coronary Intervention versus Optimal Medical Therapy in Patients with Chronic Total Occlusion: A Meta-Analysis.

Macherey-Meyer S, Salem K, Heyne S, Meertens M, Finke K, Mauri V J Clin Med. 2024; 13(10).

PMID: 38792462 PMC: 11122436. DOI: 10.3390/jcm13102919.


Development of a Novel Nomogram to Predict Major Adverse Cardiac Events in Patients with Chronic Total Occlusion.

Chen W, Liu J, Shi Y Int J Med Sci. 2024; 21(6):1091-1102.

PMID: 38774760 PMC: 11103394. DOI: 10.7150/ijms.94644.


Safety and feasibility of rotational atherectomy (RA) versus conventional stenting in patients with chronic total occlusion (CTO) lesions: a systematic review and meta-analysis.

Abdelaziz A, Elsayed H, Hamdaalah A, Atta K, Mechi A, Kadhim H BMC Cardiovasc Disord. 2024; 24(1):4.

PMID: 38166554 PMC: 10763069. DOI: 10.1186/s12872-023-03673-2.


References
1.
Mashayekhi K, Nuhrenberg T, Toma A, Gick M, Ferenc M, Hochholzer W . A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion: The REVASC Trial. JACC Cardiovasc Interv. 2018; 11(19):1982-1991. DOI: 10.1016/j.jcin.2018.05.041. View

2.
Byrne R, Joner M, Kastrati A . Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015; 36(47):3320-31. PMC: 4677274. DOI: 10.1093/eurheartj/ehv511. View

3.
Guo L, Zhang X, Lv H, Zhong L, Wu J, Ding H . Long-Term Outcomes of Successful Revascularization for Patients With Coronary Chronic Total Occlusions: A Report of 1,655 Patients. Front Cardiovasc Med. 2020; 7:116. PMC: 7393438. DOI: 10.3389/fcvm.2020.00116. View

4.
Xie W, Zheng F, Song X, Zhong B, Yan L . Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. Int J Cardiol. 2016; 205:65-71. DOI: 10.1016/j.ijcard.2015.12.010. View

5.
Neumann F, Sousa-Uva M, Ahlsson A, Alfonso F, Banning A, Benedetto U . 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018; 40(2):87-165. DOI: 10.1093/eurheartj/ehy394. View